Conferences

International Liver Congress – 2016

The International Liver Congress 2016 (ILC 2016), the annual meeting of the European Association for the Study of the Liver (EASL), was held in Barcelona, Spain from 13-17 April 2016.
Hepatitis C treatment

WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in September

Hepatitis C treatment

Low-cost generic hepatitis C drugs match branded products in viral response

Hepatitis C treatment

Does having HIV affect response to hepatitis C treatment?

Hepatitis C treatment

Hepatitis C therapy improves quality of life for people who inject drugs, but reinfection risk remains

Hepatitis C treatment

People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence

Hepatitis C treatment

Portugal's roll-out of HCV therapy with DAAs achieves impressive results

Hepatitis C treatment

DAAs achieve excellent outcomes in real-world settings

Hepatitis C transmission & prevention

High incidence of HCV reinfection among HIV-positive MSM in Western Europe

Hepatitis C treatment

Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection

Hepatitis C treatment

Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people

Hepatitis B

Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys

Hepatitis C treatment

Shifting hepatitis C treatment to primary care providers could expand availability

New & experimental hepatitis C treatment

Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients

Hepatitis C treatment

Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need

Hepatitis C treatment

$300 hepatitis C combination to enter clinical trials